News

Reportedly, Dishman Pharmaceuticals has started construction at its proposed SEZ site, near Ahmedabad, Gujrat, India, in the last week of March, after receiving funds from IDBI and Bank

The randomised, double-blind, placebo-controlled study is expected to investigate the safety, tolerability and pharmacokinetic profile of NRM8499 in a group of up to 84 young and elderly healthy

The Sysmex XT-4000i provides 34 parameters, including the advanced clinical parameters, IG (Immature Granulocyte) and RET-He (Reticulocyte Hemoglobin Equivalent) and a Body Fluid specific mode. It utilizes Sysmex’s

Neuroges said that in November 2009, Qutenza was approved by the FDA for the management of neuropathic pain associated with PHN. Qutenza is the prescription-strength topical treatment for

Celsis claimed that LC-MS/MS allows the analysts to separate, quantify and identify elements in complex mixtures. The testing method works by using HPLC to initially separate the compounds,

Ser-120 is a new, nasally administered clinical drug candidate in Phase III clinical trials being investigated for its safety and efficacy in relieving the symptoms of nocturia and

Galantamine is a drug for Alzheimer’s disease and chemically known as galantamine hydrobromide (hereinafter called galantamine). Following the development of Galantamine by Janssen Pharmaceutica, for the treatment of

FY 2009 gross profit increased 96% to $39m, compared to $19.9m for FY2008 and gross margin increased 1,470 basis points to 73.2%. Operating expenses were $23.9m, up 97.7%

The relationship is expected to focus on the evaluation of MDRNA’s proprietary di-alkylated amino acids (DiLA2) platform and UsiRNA constructs for RNA interference (RNAi). This marks MDRNA’s fourth